Explore the words cloud of the rSAMs-NANO project. It provides you a very rough idea of what is the project "rSAMs-NANO" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||185˙857 €|
|EC max contribution||185˙857 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2018-09-03 to 2020-09-02|
Take a look of project's partnership.
This proposal concerns Reversible Self-assembled Monolayers (rSAMs) as dynamic nanoparticle shells for multivalent interactions at biointerfaces. Current drug design and diagnostics are exploring the multivalency concept, i.e. binding of biological targets via multiple weak interactions. In contrast to classical drug design relying on high-affinity inhibitors, this relies on dendritic architectures featuring a high density of ligands, e.g. saccharides, capable of simultaneously interacting with biointerfacial receptors. This strategy can be used to inhibit the virus entry by blocking the receptor at the early stages of infection and the concept is being explored as antiviral drugs and in virus sensing. However, in current systems ligands are covalently fixed on the particle surface. This prevents control over the ligand distribution and composition which compromises selectivity and affinity of the interactions. rSAMs are pH-switchable versions of thiol-SAMs. They are tunable with respect to the nature of the head group and layer order and stability while featuring pH responsiveness and the dynamic nature of non-covalently build assemblies e.g. lipid bilayers. Ligand decorated rSAMs therefore feature strongly enhanced affinities for multivalent targets. The main aims of this proposal are: 1) to investigate the use of rSAMs as dynamic nanoparticle shells for multivalent inhibition of viruses and 2) to assess such systems as nanoplasmonic sensors for antibody-free ultrasensitive, robust and rapid in situ virus detection. Under 1) we will select model pathogens, e.g. Ebola and prepare a series of saccharide terminated amidines for the first generation dynamic shell nanoparticles.Their efficiency will be assessed in infection assays using artificial virus particles Under 2) we will develop influenza virus sensors with subtyping capability within human and animal virus strains. The sensors will be validated with respect to benchmark assays.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RSAMS-NANO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RSAMS-NANO" are provided by the European Opendata Portal: CORDIS opendata.
REstoring myocardial repair capacity via the modulation of MAcrophage-mediated cytoKINe secretion.Read More
Deep-learning models of CRISPR-engineered cells define a rulebook of cellular transdifferentiationRead More
Drought coping strategies in southern Africa 1966-2016Read More